Monash IVF Group (MVF.AX) Stock Price

Monash IVF Group Price

ASX·CLOSED
0.70AUD+0.0050 (+0.72 %)
Market closed

Revenue has compounded at 8.9% per year over the past 15 years to 271.92 M AUD. Earnings per share have grown at 17.1% per year over the last 11 years. Monash IVF Group's net margin stands at 9.2%, down from 13.8% several years earlier. Monash IVF Group currently offers a dividend yield of about 5.31%. The payout ratio is around 58% of earnings. Analysts set a median price target of 0.86 AUD, implying 22.4% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

Monash IVF Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Monash IVF Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Monash IVF Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Monash IVF Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Monash IVF Group Stock Price History
DateMonash IVF Group Price
7/31/20260.70 AUD
7/30/20260.69 AUD
7/29/20260.69 AUD
7/28/20260.67 AUD
7/27/20260.68 AUD
7/24/20260.65 AUD
7/23/20260.68 AUD
7/22/20260.67 AUD
7/21/20260.68 AUD
7/20/20260.69 AUD
7/17/20260.69 AUD
7/16/20260.70 AUD
7/15/20260.70 AUD
7/14/20260.71 AUD
7/13/20260.71 AUD
7/10/20260.71 AUD
7/9/20260.70 AUD
7/8/20260.70 AUD
7/7/20260.71 AUD
7/6/20260.70 AUD
7/3/20260.71 AUD
7/2/20260.71 AUD
7/1/20260.72 AUD
6/30/20260.73 AUD
6/29/20260.72 AUD
6/26/20260.71 AUD
6/25/20260.72 AUD
6/24/20260.71 AUD
6/23/20260.71 AUD
6/22/20260.71 AUD
6/19/20260.71 AUD
6/18/20260.74 AUD
6/17/20260.69 AUD
6/16/20260.69 AUD
6/15/20260.70 AUD
6/12/20260.69 AUD
6/11/20260.67 AUD
6/10/20260.69 AUD
6/9/20260.70 AUD
6/5/20260.69 AUD
6/4/20260.69 AUD
6/3/20260.71 AUD
6/2/20260.70 AUD
6/1/20260.71 AUD
5/29/20260.71 AUD
5/28/20260.71 AUD
5/27/20260.71 AUD
5/26/20260.71 AUD
5/25/20260.72 AUD
5/22/20260.71 AUD
5/21/20260.71 AUD
5/20/20260.71 AUD
5/19/20260.72 AUD
5/18/20260.71 AUD
5/15/20260.73 AUD
5/14/20260.73 AUD
5/13/20260.73 AUD
5/12/20260.74 AUD
5/11/20260.75 AUD
5/8/20260.75 AUD
5/7/20260.75 AUD
5/6/20260.75 AUD
5/5/20260.74 AUD
5/4/20260.74 AUD
5/1/20260.74 AUD
4/30/20260.73 AUD
4/29/20260.73 AUD
4/28/20260.74 AUD
4/27/20260.73 AUD
4/24/20260.73 AUD
4/23/20260.75 AUD
4/22/20260.74 AUD
4/21/20260.73 AUD
4/20/20260.72 AUD
4/17/20260.76 AUD
4/16/20260.76 AUD
4/15/20260.76 AUD
4/14/20260.76 AUD
4/13/20260.77 AUD
4/10/20260.67 AUD
4/9/20260.67 AUD
4/8/20260.68 AUD
4/7/20260.65 AUD
4/2/20260.66 AUD
4/1/20260.66 AUD
3/31/20260.66 AUD
3/30/20260.63 AUD
3/27/20260.64 AUD
3/26/20260.64 AUD
3/25/20260.65 AUD
3/24/20260.66 AUD
3/23/20260.64 AUD
3/20/20260.63 AUD
3/19/20260.64 AUD
3/18/20260.64 AUD
3/17/20260.64 AUD
3/16/20260.64 AUD
3/13/20260.64 AUD
3/12/20260.63 AUD
3/11/20260.65 AUD
3/10/20260.65 AUD
3/9/20260.64 AUD
3/6/20260.66 AUD
3/5/20260.67 AUD
2/26/20260.71 AUD
2/25/20260.69 AUD
2/24/20260.71 AUD
2/23/20260.73 AUD
2/20/20260.73 AUD
2/19/20260.72 AUD
2/18/20260.72 AUD
2/17/20260.71 AUD
2/16/20260.71 AUD
2/13/20260.70 AUD
2/12/20260.71 AUD
2/11/20260.72 AUD
2/10/20260.72 AUD
2/9/20260.70 AUD
2/6/20260.69 AUD
2/5/20260.70 AUD
2/4/20260.71 AUD
2/3/20260.71 AUD
2/2/20260.71 AUD
1/30/20260.71 AUD
1/29/20260.71 AUD
1/28/20260.73 AUD
1/27/20260.75 AUD
1/23/20260.75 AUD
1/22/20260.74 AUD
1/21/20260.75 AUD
1/20/20260.74 AUD
1/19/20260.74 AUD
1/16/20260.75 AUD
1/15/20260.75 AUD
1/14/20260.76 AUD
1/13/20260.75 AUD
1/12/20260.75 AUD
1/9/20260.75 AUD
1/8/20260.75 AUD
1/7/20260.75 AUD
1/6/20260.76 AUD
1/5/20260.75 AUD
1/2/20260.75 AUD
12/31/20250.74 AUD
12/30/20250.74 AUD
12/29/20250.73 AUD
12/24/20250.74 AUD
12/23/20250.82 AUD
12/22/20250.82 AUD
12/19/20250.82 AUD
12/18/20250.82 AUD
12/17/20250.82 AUD
12/16/20250.82 AUD
12/15/20250.82 AUD
12/12/20250.82 AUD
12/11/20250.82 AUD
12/10/20250.82 AUD
12/9/20250.84 AUD
12/8/20250.85 AUD
12/5/20250.84 AUD
12/4/20250.86 AUD
12/3/20250.86 AUD
12/2/20250.86 AUD
12/1/20250.87 AUD
11/28/20250.85 AUD
11/27/20250.85 AUD
11/26/20250.87 AUD
11/25/20250.86 AUD
11/24/20250.88 AUD
11/21/20250.61 AUD
11/20/20250.62 AUD
11/19/20250.59 AUD
11/18/20250.59 AUD
11/17/20250.60 AUD
11/14/20250.61 AUD
11/13/20250.61 AUD
11/12/20250.64 AUD
11/11/20250.66 AUD
11/10/20250.67 AUD
11/7/20250.67 AUD
11/6/20250.68 AUD
11/5/20250.67 AUD
11/4/20250.69 AUD
11/3/20250.69 AUD
10/31/20250.69 AUD
10/30/20250.70 AUD
10/29/20250.70 AUD
10/28/20250.69 AUD
10/27/20250.71 AUD
10/24/20250.71 AUD
10/23/20250.71 AUD
10/22/20250.72 AUD
10/21/20250.73 AUD
10/20/20250.73 AUD
10/17/20250.72 AUD
10/16/20250.74 AUD
10/15/20250.73 AUD
10/14/20250.73 AUD
10/13/20250.73 AUD
10/10/20250.74 AUD
10/9/20250.72 AUD
10/8/20250.71 AUD
10/7/20250.71 AUD
10/6/20250.70 AUD
10/3/20250.71 AUD
10/2/20250.69 AUD
10/1/20250.70 AUD
9/30/20250.67 AUD
9/29/20250.67 AUD
9/26/20250.66 AUD
9/25/20250.66 AUD
9/24/20250.67 AUD
9/23/20250.68 AUD
9/22/20250.67 AUD
9/19/20250.67 AUD
9/18/20250.67 AUD
9/17/20250.69 AUD
9/16/20250.68 AUD
9/15/20250.68 AUD
9/12/20250.67 AUD
9/11/20250.68 AUD
9/10/20250.68 AUD
9/9/20250.70 AUD
9/8/20250.71 AUD
9/5/20250.70 AUD
9/4/20250.70 AUD
9/3/20250.70 AUD
9/2/20250.71 AUD
9/1/20250.71 AUD
8/29/20250.71 AUD
8/28/20250.70 AUD
8/27/20250.68 AUD
8/26/20250.67 AUD
8/25/20250.69 AUD
8/22/20250.70 AUD
8/21/20250.80 AUD
8/20/20250.82 AUD
8/19/20250.81 AUD
8/18/20250.82 AUD
8/15/20250.83 AUD
8/14/20250.82 AUD
8/13/20250.81 AUD
8/12/20250.81 AUD
8/11/20250.81 AUD
8/8/20250.80 AUD
8/7/20250.81 AUD
8/6/20250.81 AUD
8/5/20250.80 AUD
8/4/20250.79 AUD
Access this data via the Eulerpool API
Get Free API Key

Monash IVF Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
213.59 M AUD
33.12 M AUD
21.84 M AUD
Jan 1, 2024
254.96 M AUD
-5.61 M AUD
-6.53 M AUD
Jan 1, 2025
271.92 M AUD
44.17 M AUD
25.01 M AUD
Jan 1, 2026 (e)
265.11 M AUD
34.20 M AUD
17.53 M AUD
Jan 1, 2027 (e)
277.02 M AUD
35.74 M AUD
19.34 M AUD
Jan 1, 2028 (e)
288.81 M AUD
37.26 M AUD
21.96 M AUD
Jan 1, 2029 (e)
295.49 M AUD
0.00 AUD
0.00 AUD
Jan 1, 2030 (e)
315.43 M AUD
0.00 AUD
0.00 AUD

Monash IVF Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 10:25 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
156.00155.00150.00151.00145.00183.00192.00213.00254.00271.00265.00277.00288.00295.00315.00336.00
25.81-0.64-3.230.67-3.9726.214.9210.9419.256.69-2.214.533.972.436.786.67
91.0391.6190.6790.0788.9789.0789.5889.6789.7689.3089.3089.3089.3089.3089.3089.30
142.00142.00136.00136.00129.00163.00172.00191.00228.00242.00236.64247.36257.18263.43281.29300.04
45.0044.0033.0032.0021.0038.0028.0033.00-5.0044.0034.0035.0037.00–––
28.8528.3922.0021.1914.4820.7714.5815.49-1.9716.2412.8312.6412.85–––
28.0029.0021.0019.0011.0025.0018.0021.00-6.0025.0017.0019.0021.00–––
33.333.57-27.59-9.52-42.11127.27-28.0016.67-128.57-516.67-32.0011.7610.53–––
0.120.130.090.090.030.060.060.060.070.040.020.020.02–––
33.338.33-30.77–-66.67100.00––16.67-42.86-50.00–––––
253.16253.03252.44252.62258.10390.94391.54392.43389.63390.96390.96390.96390.96390.96390.96390.96
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Monash IVF Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Monash IVF Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Monash IVF Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Monash IVF Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Monash IVF Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Monash IVF Group stock margins

The Monash IVF Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Monash IVF Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Monash IVF Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
89.17 %
21.05 %
13.80 %
Jan 1, 2022
89.71 %
14.75 %
9.57 %
Jan 1, 2023
89.51 %
15.51 %
10.22 %
Jan 1, 2024
89.57 %
-2.20 %
-2.56 %
Jan 1, 2025
89.16 %
16.25 %
9.20 %
Jan 1, 2026 (e)
89.16 %
12.90 %
6.61 %
Jan 1, 2027 (e)
89.16 %
12.90 %
6.98 %
Jan 1, 2028 (e)
89.16 %
12.90 %
7.60 %

Monash IVF Group Stock Revenue, EBIT, Earnings per Share

The Monash IVF Group earnings per share therefore indicates how much revenue Monash IVF Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.47 AUD
0.10 AUD
0.06 AUD
Jan 1, 2022
0.49 AUD
0.07 AUD
0.05 AUD
Jan 1, 2023
0.54 AUD
0.08 AUD
0.06 AUD
Jan 1, 2024
0.65 AUD
-0.01 AUD
-0.02 AUD
Jan 1, 2025
0.70 AUD
0.11 AUD
0.06 AUD
Jan 1, 2026 (e)
0.68 AUD
0.09 AUD
0.04 AUD
Jan 1, 2027 (e)
0.71 AUD
0.09 AUD
0.05 AUD
Jan 1, 2028 (e)
0.74 AUD
0.10 AUD
0.06 AUD

Monash IVF Group business model & stock analysis

The Monash IVF Group Ltd is a company in Australia specializing in reproductive medicine. It was founded in 1970 by Professor Gab Kovacs, who is considered one of the pioneers in the field of in-vitro fertilization (IVF). The company's history began in a small laboratory in Melbourne, where the first successful IVF procedures were performed. Over time, Monash IVF grew and expanded its focus to include other reproductive treatments such as donor egg programs, sperm donation, and cryopreservation. Monash IVF Group Ltd has since become a leading provider in Australia, with 19 clinics throughout the country. The company is not only active in Australia but also operates clinics in Malaysia and Vietnam. The business model of Monash IVF Group Ltd is centered around helping couples and individuals fulfill their desire to have children. The company offers a wide range of treatments tailored to the individual needs and circumstances of each patient. Among the services offered are not only IVF, donor egg programs, and sperm donation but also other technologies such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD). Monash IVF Group Ltd sees itself as an all-rounder and therefore also offers psychological support and guidance during and after treatments. One of the company's specialties is its comprehensive research work. The Monash IVF Group has a specialized research department actively involved in researching new reproductive technologies. The company collaborates closely with universities and leading scientific institutes to gain the latest insights in this field and achieve the best possible outcomes for its patients. Monash IVF Group Ltd is divided into various divisions, each with different focuses and offerings. The main division is the Monash IVF Clinic, specializing in reproductive health and fertility. Here, all common IVF and fertility treatments are offered. Another division is Monash IVF Fertility Diagnostics, specializing in diagnostics and screening of fertility and reproductive problems. State-of-the-art diagnostic procedures for evaluating male and female fertility are used here. Monash IVF Genomics is another division offering genetic counseling, screening, and diagnostics. Here, couples can determine their genetic risk factors for fertility problems and receive support in making the best possible decisions regarding family planning. In addition to these divisions, Monash IVF Group Ltd also offers specialized services. For example, there is the Monash IVF Donor Program, specializing in the facilitation of anonymous and open donor programs. The Monash IVF DNA Matching can also assist in the search for genetic relatives by utilizing advanced DNA profiling. As a leading company in the field of fertility, Monash IVF Group Ltd offers a wide range of products and services to help couples and individuals fulfill their desire to have children. With a long history of innovation and research, as well as a variety of divisions and offerings, the company is an important provider of reproductive medicine in Australia and beyond.

Monash IVF Group SWOT Analysis

Strengths

[ { "text": "Leading", "heading": "1." } ]

Monash IVF Group Ltd is a renowned and respected reproductive healthcare provider, with a strong reputation and track record in the industry.

[ { "text": "Established", "heading": "2." } ]

The company has built a recognized brand name and enjoys a significant market presence, providing a competitive advantage in attracting patients and healthcare professionals.

[ { "text": "Comprehensive", "heading": "3." } ]

Monash IVF Group offers a broad range of reproductive services, including fertility treatments, genetic screening, donor programs, and specialized diagnostic procedures. This extensive service offering caters to a wide range of patient needs.

Weaknesses

[ { "text": "Reliance", "heading": "1." } ]

Monash IVF Group's primary revenue stream comes from assisted reproductive technology, making the company vulnerable to any decline in demand or changes in government regulations related to this field.

[ { "text": "Regulatory", "heading": "2." } ]

The reproductive healthcare industry is subject to strict regulations and oversight. Any changes in regulations, compliance requirements, or licensing conditions may impact the company's operations and financial performance.

[ { "text": "Relatively", "heading": "3." } ]

The cost of reproductive treatments and associated procedures can be relatively high, making it less accessible for certain individuals or causing potential financial strain on patients.

Opportunities

[ { "text": "Growing", "heading": "1." } ]

There is an increasing demand for reproductive services due to various factors such as delayed pregnancies, changing lifestyles, and rising infertility rates. Monash IVF Group can leverage this growth opportunity by expanding its service offerings and geographic reach.

[ { "text": "Technological", "heading": "2." } ]

Advancements in reproductive technology and genetic testing provide opportunities for Monash IVF Group to enhance its offerings, improve success rates, and develop innovative solutions to address patients' needs.

Threats

[ { "text": "Intense", "heading": "1." } ]

The reproductive healthcare industry is highly competitive, with numerous local and international providers. Monash IVF Group faces the risk of losing market share to competitors offering similar services or attractive pricing strategies.

[ { "text": "Economic", "heading": "2." } ]

Fluctuations in the economy, changes in healthcare funding, and insurance coverage can impact demand for reproductive services, potentially affecting Monash IVF Group's financial performance.

[ { "text": "Ethical", "heading": "3." } ]

Reproductive healthcare involves sensitive ethical and legal considerations such as embryo storage, surrogacy agreements, and genetic manipulation. Non-compliance or controversies related to these areas could harm the company's reputation and create legal challenges.

Monash IVF Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Monash IVF Group historical P/E ratio, EBIT multiple, and P/S ratio

Monash IVF Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Monash IVF Group shares outstanding

The number of shares of Monash IVF Group was 390.96 M in 2025. This indicates how many shares Monash IVF Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
390.94 M Stocks
Jan 1, 2022
391.54 M Stocks
Jan 1, 2023
392.43 M Stocks
Jan 1, 2024
389.63 M Stocks
Jan 1, 2025
390.96 M Stocks
Jan 1, 2026 (e)
390.96 M Stocks
Jan 1, 2027 (e)
390.96 M Stocks
Jan 1, 2028 (e)
390.96 M Stocks

Monash IVF Group Dividend History

12 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.01AUDYTD—1×
Mar 3, 20260.01AUD↓ 67.7%1/1
20250.04AUD↓ 48.0%1×
Mar 6, 20250.04AUD↑ 4.0%1/1
20240.07AUD↑ 13.6%2×
20230.06AUD 0.0%2×
20220.06AUD↑ 4.8%2×
20210.06AUD↑ 100.0%2×
20200.03AUD↓ 65.0%1×
20190.09AUD 0.0%2×
20180.09AUD↓ 31.8%2×
20170.13AUD↑ 3.5%2×

Monash IVF Group dividend history and estimates

In 2025, Monash IVF Group paid a dividend amounting to 0.04 AUD. Dividend means that Monash IVF Group distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
0.06 AUD
0.00 AUD
Jan 1, 2022
0.06 AUD
0.00 AUD
Jan 1, 2023
0.06 AUD
0.00 AUD
Jan 1, 2024
0.07 AUD
0.00 AUD
Jan 1, 2025
0.04 AUD
0.00 AUD
Jan 1, 2026 (e)
0.01 AUD
0.01 AUD
Jan 1, 2027 (e)
0.00 AUD
0.02 AUD
Jan 1, 2028 (e)
0.00 AUD
0.02 AUD

Monash IVF Group dividend payout ratio

In 2025, Monash IVF Group had a payout ratio of 58.04%. The payout ratio indicates the percentage of the company's profits that Monash IVF Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
92.59 %
Jan 1, 2022
133.74 %
Jan 1, 2023
112.85 %
Jan 1, 2024
-425.17 %
Jan 1, 2025
58.04 %
Jan 1, 2026 (e)
53.51 %
Jan 1, 2027 (e)
48.51 %
Jan 1, 2028 (e)
42.72 %

Current Monash IVF Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
60.00 % (6)
Hold
40.00 % (4)
Sell
0.00 % (0)
12M Price Target
0.86
Last Price
0.69
Currency
AUD
12M Return Potential
25.08 %
LTM Return
0 %

Monash IVF Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/19/20240.03AUD-115.65 MAUD-2024 Q2
8/24/20230.03AUD-114.69 MAUD-2023 Q4
2/15/20230.04AUD-111.65 MAUD-2023 Q2
8/26/20220.02AUD-96.93 MAUD-2022 Q4
2/17/20220.03AUD-98.45 MAUD-2022 Q2
8/24/20210.03AUD-77.14 MAUD-2021 Q4
2/24/20210.04AUD-88.30 MAUD-2021 Q2
8/24/20200.01AUD-57.85 MAUD-2020 Q4
8/26/20190.05AUD-77.34 MAUD-2019 Q4

EESG©

Eulerpool ESG Scorecard© for the Monash IVF Group stock

64/100
69
Environment
80
Social
44
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees92
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Monash IVF Group shareholder structure

% Name
2.42012%
DFA Australia Ltd.
DFA Australia Ltd.
1.63851%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.50383%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.31023%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.30894%
Mellon Investments Corporation
Mellon Investments Corporation
0.18791%
Knaap (Michael)
Knaap (Michael)

Monash IVF Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
75.7%
Float Shares
-
Shares Outstanding
-

Monash IVF Group Executives and Management Board

9 members · avg. age 76 · 33 % women

HH

Mr. Hamish Hamilton

Chief Operating Officer · since 2020

608,353.00 AUD

Management

MJ

Mr. Malik Jainudeen

Acting Chief Executive Officer, Company Secretary · since 2025

583,848.00 AUD
AM

Mr. Andrew Maclachlan

Interim Chief Financial Officer

–

Board of Directors

RH

Dr. Richard Henshaw (84)

Executive Director

393,899.00 AUD
RD

Mr. Richard Davis (67)

Non-Executive Independent Chairman of the Board

183,694.00 AUD
ZP

Ms. Zita Peach

Non-Executive Independent Director

117,030.00 AUD
NB

Mr. Neil Broekhuizen

Non-Executive Independent Director

107,654.00 AUD
CW

Ms. Catherine West

Non-Executive Independent Director

107,653.00 AUD
CA

Ms. Catherine Aston

Non-Executive Independent Director

35,884.00 AUD

Monash IVF Group Supply Chain

Monash IVF Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
8 companies
#NameTrend
1
HSBC Holdings
Supplier·Customer·Banks·GB
0.68
0.82
-0.14
0.58
0.71
0.81
2
Challenger
Supplier·Customer·Diversified Financial Services·AU
0.05
-0.13
0.07
0.51
0.66
0.74
3
General Electric
Supplier·Industrial Conglomerates·US
0.24
0.94
0.39
-0.40
-0.73
0.64
4
JPMorgan Chase
Supplier·Customer·Banks·US
0
0.32
0.14
-0.70
-0.68
0.57
5
BlackRock
Supplier·Customer·Capital Markets·US
-0.36
0.65
0.26
-0.71
-0.75
0.49
#NameTrend
1
Memphasys
Supplier·Customer·Life Sciences Tools & Services·AU
0.36
0.89
0.53
-0.61
-0.23
-0.62

Frequently asked questions about Monash IVF Group

Monash IVF Group Ltd is primarily active in the healthcare and biotechnology industries.

Some of the main competitors of Monash IVF Group Ltd in the market include Virtus Health Limited, Healthscope Limited, and Genea Limited. These companies also operate in the fertility services sector and compete with Monash IVF Group Ltd in providing reproductive and infertility treatments.

Monash IVF Group Ltd operates as a leading fertility provider in Australia. The company's business model focuses on offering a comprehensive range of assisted reproductive services. Monash IVF Group specializes in fertility treatments, including in vitro fertilization (IVF), sperm and egg donation, genetic testing, and surrogacy. With a dedicated team of specialists and advanced laboratory facilities, Monash IVF Group aims to help individuals and couples achieve their dream of having a family. By combining cutting-edge technology, personalized care, and research advancements, the company strives to deliver the highest quality fertility care to its patients.

Monash IVF Group Ltd, founded in 2000, is a leading Australian fertility services provider. Specializing in assisted reproductive technology and treating infertility, the company has a rich history of pioneering advancements. Monash IVF Group Ltd operates a network of fertility clinics, offering comprehensive services such as in vitro fertilization, fertility testing, and sperm and egg donation. With a team of highly skilled specialists, the company is committed to delivering exceptional patient care and achieving strong success rates in fertility outcomes. Monash IVF Group Ltd has grown to become a trusted name in the fertility industry, consistently providing hope and support to individuals and couples seeking to start or expand their families.

Monash IVF Group Ltd has achieved several significant milestones. The company has a strong track record of delivering high success rates in assisted reproductive technologies such as in vitro fertilization (IVF) and has assisted in the birth of over 30,000 babies. Monash IVF Group Ltd has also pioneered innovative fertility treatments and technologies, including the development of genetic testing for embryos and advancements in egg freezing techniques. The company's commitment to research and clinical excellence has made them a leading player in the fertility industry, earning them a reputation for delivering exceptional patient outcomes and maintaining a position at the forefront of reproductive medicine.

Monash IVF Group Ltd primarily operates in Australia and Malaysia. Australia is its main market, where it has multiple clinics located across the country. Additionally, the company has a significant presence in Malaysia, offering fertility services through its strategic partnership with Sunfert International. Monash IVF Group Ltd's focus on these countries and regions allows it to provide comprehensive reproductive and fertility services to patients, including in vitro fertilization (IVF), genetic testing, and other related treatments.

Monash IVF Group Ltd represents values of excellence, innovation, and patient-centered care. With a corporate philosophy focused on fulfilling the dreams of parenthood, Monash IVF Group Ltd is dedicated to providing cutting-edge fertility treatments and personalized support to couples and individuals. By leveraging its extensive experience and technological advancements, the company strives to deliver superior reproductive medicine services. Monash IVF Group Ltd maintains its commitment to the highest ethical standards, transparency, and fostering a compassionate and inclusive environment for its patients.

Analysts currently set an average price target of 0.85 AUD for the Monash IVF Group stock (median: 0.86 AUD), implying +23.6 % versus the latest price. The consensus is based on 10 analyst ratings.

Monash IVF Group Analyst Price Targets 2026

10 analysts currently rate the Monash IVF Group stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Monash IVF Group to generate revenue of 265.11 M AUD and earnings per share of 0.04 AUD.

Monash IVF Group Analyst Price Targets 2026

Converted at the current exchange rate, the Monash IVF Group share trades at 0.43 EUR (0.70 AUD).

The Monash IVF Group share (MVF.AX) is listed on 3 stock exchanges, including: Frankfurt (MIS.F), München (MIS.MU), ASX (MVF.AX).

Monash IVF Group Ltd is an Australian-based company that specializes in providing assisted reproductive technology (ART) and the investigation and treatment of infertility. The company currently operates multiple fertility clinics and laboratories in Australia and New Zealand. The company offers a wide range of reproductive and fertility services that focus on meeting the specific needs and requirements of each customer. This includes in-vitro fertilization (IVF), intrauterine insemination (IUI), sperm and egg donation, as well as preimplantation diagnosis (PID) and genetic testing. Monash IVF Group has also specialized in researching and developing new technological approaches for assisted reproduction. This includes an extensive research program that focuses on investigating factors that influence fertility, such as lifestyle factors, environmental influences, and genetic predispositions. Another important aspect of the company is the education of doctors, nurses, and other professionals in assisted reproduction. Monash IVF Group offers a variety of courses, training, and workshops to constantly improve and develop knowledge and skills in the field of assisted reproductive technologies. In addition to its clinical services and research program, Monash IVF Group also operates its own diagnostic laboratory that offers a wide range of tests for diagnosing infertility. This includes hormone analysis, semen analysis, and genetic testing. The company is also able to extend its services to international customers. Monash IVF Group has a strong presence in Asia and currently operates clinics in Malaysia and Singapore. Overall, Monash IVF Group has a comprehensive business model that focuses on providing high-quality reproductive and fertility services, conducting innovative research programs, educating professionals, and expanding international markets. The company is well-positioned to grow its customer base and expand its range of services and products to meet the changing demands in the field of assisted reproductive technology.

The expected revenue of Monash IVF Group is 265.11 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Monash IVF Group is 17.53 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Monash IVF Group is currently 15.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Monash IVF Group stock.

The price-to-sales ratio (P/S) of Monash IVF Group is currently 1.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Monash IVF Group stock.

The Eulerpool Quality Score for Monash IVF Group is 5/10.

The ISIN of Monash IVF Group is AU000000MVF3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Monash IVF Group is A116LZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Monash IVF Group is MVF.AX. The ticker symbol is used to trade Monash IVF Group shares on the stock exchange.

Over the past 12 months, Monash IVF Group paid a dividend of 0.04 AUD . This corresponds to a dividend yield of about 5.31 %. For the coming 12 months, Monash IVF Group is expected to pay a dividend of 0.02 AUD.

The current dividend yield of Monash IVF Group is 5.31 %.

Monash IVF Group pays a dividend, distributed in the months of , , , .

Monash IVF Group paid dividends every year for the past 11 years.

For the upcoming 12 months, dividends amounting to 0.02 AUD are expected. This corresponds to a dividend yield of 3.43 %.

Monash IVF Group is assigned to the 'Health' sector.

In the year 2025, Monash IVF Group distributed 0.07 AUD as dividends.

The dividends of Monash IVF Group are distributed in AUD.

All fundamentals and in-depth analysis of Monash IVF Group

Our stock analysis for Monash IVF Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Monash IVF Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Monash IVF Group Stock
Monash IVF Group Revenue→
Monash IVF Group Stock
Monash IVF Group Net Income→
Monash IVF Group Stock
Monash IVF Group P/E→
Monash IVF Group Stock
Monash IVF Group P/S→
Monash IVF Group Stock
Monash IVF Group EBIT→
Monash IVF Group Stock
Monash IVF Group Dividend→
Monash IVF Group Stock
Monash IVF Group Directors Dealings→
Monash IVF Group Stock
Monash IVF Group Stocks→
Monash IVF Group Stock
Monash IVF Group Market capitalization→
Monash IVF Group Stock
Monash IVF Group Debt→
Monash IVF Group Stock
Monash IVF Group Liabilities→
Monash IVF Group Stock
Monash IVF Group Equity→
Monash IVF Group Stock
Monash IVF Group AAQS→
Monash IVF Group Stock
Monash IVF Group Employees→
Monash IVF Group Stock
Monash IVF Group ROE→
Monash IVF Group Stock
Monash IVF Group ROA→
Monash IVF Group Stock
Monash IVF Group ROCE→
Monash IVF Group Stock
Monash IVF Group News→
Monash IVF Group Stock
Monash IVF Group Analyst Price Targets→

Health Stocks

Mono PharmacareMolina HealthcareMonopar TherapeuticsMolecureMonsenso A/SMoleculin BiotechMonte Rosa TherapeuticsMolecule HoldingsMoonLake ImmunotherapeuticsMolecular Partners AG ADRMorepen LaboratoriesMolecular PartnersAll Stocks A–Z →